Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
Author:
Contact Author:

Affiliation:

Clc Number:

Fund Project:


Conflicts of Interest: Yuan A, None; Ahmad BU, None; Xu D, None; Martin DF, None; Sears JE, None; Schachat AP, None; Singh RP: consultant for Thrombogenics, Regeneron, Alcon, and Bausch and Lomb; Kaiser PK: consultant for Bayer, Regeneron, Genentech, Kanghong, Novartis, and Alcon; Ehlers JP: speaker for Regeneron, consultant and speaker for Thrombogenics.

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM:To compare the efficacy of ranibizumab and bevacizumab for macular edema due to retinal vein occlusion (RVO).METHODS:A retrospective study was conducted at a single academic institution. Eighty-one patients na?ve to anti-VEGF therapy with RVO and macular edema were identified. Twenty-six eyes were treated with ranibizumab, 33 eyes with bevacizumab, and 22 eyes with bevacizumab then switched to ranibizumab (crossover). The main outcome was change in visual acuity at 3 months, 6 months, and final visit.RESULTS:The mean visual acuity improved from 20/80 to 20/40 in the ranibizumab (R) group and from 20/125 to 20/60 in the bevacizumab (B) group (P=0.66). The mean change in central subfield thickness (CST) was -186 and -212μm, respectively (P=0.69). Mean time between injections was 94±21.1d in the R group and 103.8±10.5d in the B group (P=0.78). In the crossover group, mean initial visual acuity was 20/125, reached 20/60 at crossover, and remained 20/60 at conclusion (P=0.91).CONCLUSION:Both ranibizumab and bevacizumab are effective for the treatment of RVO and appear to have similar visual and anatomic outcomes. Changing treatments from bevacizumab to ranibizumab did not result in further gains in visual acuity.

    Reference
    Related
    Cited by
Get Citation

Alex Yuan, Baseer U. Ahmad, David Xu, et al. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Int J Ophthalmol, 2014,7(1):86-91

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:November 01,2013
  • Revised:January 10,2014
  • Adopted:January 10,2014
  • Online: February 20,2014
  • Published: